The purpose of this study is to determine the efficacy and safety of abituzumab in subjects withsystemic sclerosis-associated interstitial lung disease (SSc-ILD).Abituzumab is an investigational drug that is being evaluated for the treatment of patients withsystemic sclerosis (SSc)-associated interstitial…
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to…
This study is designed to examine the efficacy and safety profile of dupilumab over one year in a population of asthmatic children in need for an additional treatment to their current maintenance management. Patients are randomized to either dupilumab or matching placebo administered standard care for a maximum treatment duration of 52 weeks. The…
The purpose of this global study is to provide evidence of the efficacy and safety of 210 mg dose of tezepelumab administered every 4 weeks subcutaneously in adults and adolescents (12 years of age and older) with a history of asthma exacerbations and severe uncontrolled asthma receiving medium or high dose inhaled corticosteroids plus at least one…
The purpose of this study is to determine the effectiveness and safety of a study drug called abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study will also look at the following: How the study drug affects other symptoms of SSc-ILD -How safe the study drug is (i.e. if there…
Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. There are numerous manifestations of SSc that affect multiple organ systems. The major pulmonary manifestations of SSc, interstitial lung disease and…